You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

What is Nucala?

Nucala is an asthma medicine used to treat patients aged 6 years and above with a particular type of asthma called severe eosinophilic asthma. It is used with other medicines in patients whose asthma is severe and not well controlled with previous treatments.1

Nucala contains the active substance mepolizumab.1

Safety Information

For safety information on Nucala including information on who is suitable for Nucala prescription, please see the Nucala patient information leaflet (PIL). This link will take you to www.medicines.ie which is a non-GSK website.

Nucala (PIL)

Patient Information

This information is specifically for patients that have been prescribed Nucala by a Healthcare Professional registered in Ireland.

I am a patient

For further information on Nucala (mepolizumab) and potential side effects please see:

References:

  1. Nucala 100mg solution for injection in pre-filled pen patient information leaflet

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed on this website or in the product package leaflet. You can also report side effects directly to the HPRA Pharmacovigilance, Earlsfort Terrace, Dublin. Website: www.hpra.ie

By reporting side effects you can help provide more information on the safety of this medicine.

Nucala is a registered trademark of the GlaxoSmithKline group of companies.